Premium
Monitoring of relapse and remission in acute leukaemias by DNA‐fingerprint analysis
Author(s) -
Hübner G.,
Battmer K.,
Paaz U.,
Link H.
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb03173.x
Subject(s) - minisatellite , medicine , haeiii , bone marrow , transplantation , acute lymphocytic leukemia , chemotherapy , dna , polymerase chain reaction , leukemia , immunology , oncology , pathology , biology , restriction fragment length polymorphism , microsatellite , genetics , allele , lymphoblastic leukemia , gene
Summary DNA‐fingerprint (DNA‐F) analysis was successfully performed with DNA from 22 adult patients with acute leukaemia, including 13 patients with acute myeloid leukaemia (AML) and nine patients with acute lymphoblastic leukaemia (ALL). The purpose of this study was to detect differences between the leukaemic phase (at diagnosis or relapse) and remission‐phase DNA. We applied one simple repeat probe (GTG) s and one minisatellite (M13) after DNA‐digestion with different restriction endonucleases ( Hinf I and Hae III) and agarose gel electrophoresis. In 7/13 patients with AML and 5/9 patients with ALL it was possible to detect loss of bands. additional bands or band shift with at least one of the probes. Together the probes M13 and (GTG) 5 unveiled deviating fingerprint patterns in 54.6% of patients between leukaemic cells and remission‐phase leucocytes. Allogeneic bone marrow transplantation was performed on six patients. In each case the DNA‐F pattern of the donor was different from the relapse and the remission‐phase pattern. We conclude from our studies that the probes M13 and (GTG) 5 are useful in the detection of relapse and remission in acute leukaemias after chemotherapy and bone marrow transplantation.